Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Itraconazole

FDA-approved product (capsule, oral), marketed as Itraconazole, Onmel, Sporanox and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Itraconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Blastomycosis
  • Candidiasis
  • Fungal infectious disease
  • Lung disease
  • Tinea
  • Tinea unguium

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC02; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Itraconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Itraconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

    NCT05667662 · start 2023-02-01

    Registered record
    Registry ID
    NCT05667662
    Conditions
    ABPA
    Interventions
    Itraconazole Powder; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-02-01
    Completion
    2024-02-27
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionABPA
    InterventionItraconazole Powder; Placebo
    PhasePhase 2
    Registry statusTerminated

  • A Study to Assess Adverse Events and How Single and Multiple Ascending Doses of ABBV-903 Move Through the Body in Healthy Adults

    NCT05691699 · start 2023-01-03

    Registered record
    Registry ID
    NCT05691699
    Conditions
    Healthy Volunteer
    Interventions
    ABBV-903; Placebo for ABBV-903; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-01-03
    Completion
    2023-10-23
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionABBV-903; Placebo for ABBV-903; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

    NCT05594602 · start 2022-10-06

    Registered record
    Registry ID
    NCT05594602
    Conditions
    COVID-19
    Interventions
    EDP-235; EDP-235; EDP-235; Itraconazole; Carbamazepine; Quinidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-06
    Completion
    2022-12-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionEDP-235; EDP-235; EDP-235; Itraconazole +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole

    NCT05551897 · start 2022-10-04

    Registered record
    Registry ID
    NCT05551897
    Conditions
    Healthy Subjects
    Interventions
    Camizestrant; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-04
    Completion
    2022-12-28
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionCamizestrant; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects

    NCT05549531 · start 2022-10-01

    Registered record
    Registry ID
    NCT05549531
    Conditions
    Healthy
    Interventions
    ACT-1004-1239 (10 mg); Itraconazole (200 mg, o.d.)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-10-01
    Completion
    2022-10-20
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionACT-1004-1239 (10 mg); Itraconazole (200 mg, o.d.)
    PhasePhase 1
    Registry statusCompleted

  • Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome

    NCT05444946 · start 2022-06-15

    Registered record
    Registry ID
    NCT05444946
    Conditions
    Chronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis
    Interventions
    Prednisone tablet and Itraconazole; Oral itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-06-15
    Completion
    2027-02-01
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pulmonary Aspergillosis; Allergic Bronchopulmonary Aspergillosis
    InterventionPrednisone tablet and Itraconazole; Oral itraconazole
    PhaseNot applicable
    Registry statusRecruiting

  • A Prospective Study on Optimizing Treatment for ABPA

    NCT05129033 · start 2021-11-15

    Registered record
    Registry ID
    NCT05129033
    Conditions
    Allergic Bronchopulmonary Aspergillosis
    Interventions
    Prednisone tablet; itraconazole; Omalizumab
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-11-15
    Completion
    2023-12-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Bronchopulmonary Aspergillosis
    InterventionPrednisone tablet; itraconazole; Omalizumab
    PhaseNot applicable
    Registry statusUnknown

  • A Study of LY3484356 in Healthy Female Participants

    NCT04840888 · start 2021-04-26

    Registered record
    Registry ID
    NCT04840888
    Conditions
    Healthy
    Interventions
    LY3484356; Omeprazole; Itraconazole; Carbamazepine; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-04-26
    Completion
    2022-04-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLY3484356; Omeprazole; Itraconazole; Carbamazepine +1 more
    PhasePhase 1
    Registry statusCompleted

  • Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin.

    NCT04880980 · start 2021-03-15

    Registered record
    Registry ID
    NCT04880980
    Conditions
    Dermatophyte Infection; Terbinafine Adverse Reaction; Itraconazole Adverse Reaction
    Interventions
    Terbinafine Pill; Itraconazole capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-03-15
    Completion
    2022-03-15
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatophyte Infection; Terbinafine Adverse Reaction; Itraconazole Adverse Reaction
    InterventionTerbinafine Pill; Itraconazole capsule
    PhasePhase 3
    Registry statusCompleted

  • Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

    NCT04743414 · start 2021-03-02

    Registered record
    Registry ID
    NCT04743414
    Conditions
    Healthy Volunteers
    Interventions
    CTP-543
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-02
    Completion
    2021-04-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCTP-543
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

    NCT04712396 · start 2021-02-01

    Registered record
    Registry ID
    NCT04712396
    Conditions
    Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
    Interventions
    Capivasertib; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-02-01
    Completion
    2021-03-25
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
    InterventionCapivasertib; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

    NCT04586920 · start 2020-10-20

    Registered record
    Registry ID
    NCT04586920
    Conditions
    Healthy
    Interventions
    LY3509754; Placebo; Itraconazole; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-10-20
    Completion
    2022-10-14
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLY3509754; Placebo; Itraconazole; Midazolam
    PhasePhase 1
    Registry statusTerminated

  • Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

    NCT04423601 · start 2020-06-10

    Registered record
    Registry ID
    NCT04423601
    Conditions
    Healthy Subjects
    Interventions
    SHR6390 tablet; Itraconazole capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-06-10
    Completion
    2021-02-02
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionSHR6390 tablet; Itraconazole capsule
    PhasePhase 1
    Registry statusCompleted

  • A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood

    NCT03890887 · start 2019-04-12

    Registered record
    Registry ID
    NCT03890887
    Conditions
    Healthy
    Interventions
    BI 1291583; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-12
    Completion
    2019-07-29
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1291583; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RO7017773 in Healthy Participants

    NCT03774576 · start 2018-12-17

    Registered record
    Registry ID
    NCT03774576
    Conditions
    Healthy Volunteers
    Interventions
    RO7017773; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-17
    Completion
    2019-03-14
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionRO7017773; Itraconazole
    PhasePhase 1
    Registry statusCompleted